JAK1 and rheumatoid arthritis: For example, tofacitinib, baricitinib, and upadacitinib, selective oral inhibitors of JAK1/3 or JAK1/2, are approved for the treatment of rheumatoid arthritis and other inflammatory diseases [158,183,184,185,186,187].